Fluorinated gases (F-gases) play a vital role in the chemical industry and in the fields of air conditioning, refrigeration, health care, and organic synthesis. However, the direct emission of waste gases containing F-gases into the atmosphere contributes to greenhouse effects and generates toxic substances. Developing porous materials for the energy-efficient capture, separation, and recovery of F-gases is highly desired. Recently, as a highly designable porous adsorbents, metal–organic frameworks (MOFs) exhibit excellent selective sorption performance toward F-gases, especially for the recognition and separation of different F-gases with highly similar properties, showing their great potential in F-gases control and recovery. In this review, we discuss the capture and separation of F-gases and their azeotropic, near-azeotropic, and isomeric mixtures in various application scenarios by MOFs, specifically classify and analyze molecular interaction between F-gases and MOFs, and interpret the mechanisms underlying their high performance regarding both adsorption capacity and selectivity, providing a repertoire for future materials design. Challenges faced in the transformation research roadmap of MOFs adsorbent separation technologies toward F-gases are also discussed, and areas for future research endeavors are highlighted.

Tranexamic acid (TXA), a synthetic lysine analog, is a commonly used antifibrinolytic and procoagulant agent. Based on its good hemostatic efficacy, it is mainly used clinically for bleeding in trauma, various types of surgical and dental procedures and prevention of bleeding in patients with hemophilia. In recent years, studies have shown that TXA has the effects of anti-melanogenesis, anti-inflammation, anti-angiogenesis and promotes the recovery of the skin barrier, so it has been tried to be used as a treatment for hyperpigmentation and telangiectatic diseases. Oral, topical, intradermal injections and microneedling are all commonly used modes of administration. TXA for melasma is the most studied and has achieved indications in some countries, whereas it is still an off-label drug for many other dyschromia. We review the clinical use of TXA in hyperpigmentation and telangiectatic disorders other than melasma, such as post-inflammatory hyperpigmentation, Riehl’s melanosis, rosacea, and post-acne erythema, to provide more evidence for the use of TXA in these disorders, and to provide safer and more cost-effective alternatives for the treatment of these diseases.